Metabolics

Biocon Biologics has been at the forefront of addressing the growing global burden of diabetes through science-led innovation and expanded access. Leveraging decades of expertise in biologics, we are transforming diabetes care with a comprehensive portfolio of high-quality biosimilar insulins designed to improve affordability and therapeutic choice for patients worldwide. Our diabetes biosimilars are helping reshape treatment paradigms across diverse healthcare systems, supporting both early and advanced insulin-requiring patients. By combining clinical rigor, sustainable manufacturing, and a deep commitment to equity, Biocon Biologics is enabling better glycemic control and improving outcomes for millions of people living with diabetes globally.